The product was administered in once-daily doses in combination with an optimized ritonavir-boosted antiretroviral regimen. Vicriviroc is an extracellular inhibitor of HIV infection designed to block entry of
EntreMed received a no objection letter from the Therapeutic Products Directorate of Health Canada on its clinical trial application to conduct the clinical trial in leukemia patients. A
The trial will compare the efficacy and safety of peramivir administered intravenously once daily for five days versus oral oseltamivir administered twice daily for five days in adults
Target selectivity has the potential to significantly enhance efficacy of therapeutics while limiting their toxicity and side effects, therefore selectivity has long been the goal in the development
The company says it could be tapping into a potential market of over $1 billion. PLX cells are placenta derived mesenchymal stem cells expanded in the company’s proprietary
The open-label, multi-center, randomized study in chronic kidney disease (CKD) patients on hemodialysis demonstrated a statistically significant achievement of all the primary and secondary endpoints, the company said.
Preliminary results from the Phase I study, conducted to assess the safety and biological activity of the anti-IL-5 receptor MAb, suggest that the antibody-dependent cellular cytotoxicity (ADCC) enhanced
Targacept’s drug, AZD3480, acts selectively on neuronal nicotinic receptors and has been evaluated in 12 clinical trials in approximately 540 subjects. In a previous Phase IIb trial in
A fast-track designation speeds up the review process and is generally given to drugs that address an unmet need for serious or life-threatening conditions. Neurochem said that it
Inovio’s DNA delivery systems are designed with the aim of enhancing the potency of DNA-based immunotherapies and vaccines against infectious diseases and cancers. The collaboration with the National
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.